This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zitzmann, S. Articles by Schwab, M. Search for Related Content PubMed PubMed Citation Articles by Zitzmann, S. Articles by Schwab, M.

Arginine-Glycine-Aspartic Acid (RGD)-Peptide Binds to Both Tumor and Tumor-Endothelial Cells in Vivo

German Cancer Research Center, Department for Cytogenetics [S. Z., M. S.], and University of Heidelberg, Institute for Pathology, [V. E.], D-69120 Heidelberg, Germany

Targeting tumor cells or tumor vasculature by peptides is a promising strategy for delivering cytotoxic drugs for cancer therapy. The identification of efficient targeting peptides depends on the availability of informative methods for determining cellular binding specificities. Here, we have used fluorescence-activated cell-sorting (FACS) analysis in combination with an isopentane freezing method to show targeted binding of the Arg-Gly-Asp (RGD)-4C-peptide labeled with FITC, not only to endothelial cells but also to tumor cells in human breast cancer xenografts grown in nude mice. Nontumorous cells showed only background binding. This study suggests, that the RGD-4C-peptide can target tumor endothelial cells as well as tumor cells. Consequently, it should be possible to design a combination therapy approach against both targets.

This article has been cited by other articles:

				L. M. Kenny, R. C. Coombes, I. Oulie, K. B. Contractor, M. Miller, T. J. Spinks, B. McParland, P. S. Cohen, A.-M. Hui, C. Palmieri, et al. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients J. Nucl. Med., June 1, 2008; 49(6): 879 - 886. [Abstract] [Full Text] [PDF]

				M.-K. Kwon, J.-O. Nam, R.-W. Park, B.-H. Lee, J.-Y. Park, Y.-R. Byun, S.-Y. Kim, I.-C. Kwon, and I.-S. Kim Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3 Mol. Cancer Ther., June 1, 2008; 7(6): 1514 - 1522. [Abstract] [Full Text] [PDF]

				L. Cao, P. Du, S.-H. Jiang, G.-H. Jin, Q.-L. Huang, and Z.-C. Hua Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature Mol. Cancer Ther., April 1, 2008; 7(4): 851 - 861. [Abstract] [Full Text] [PDF]

				F. Furuya, C. Lu, M. C. Willingham, and S.-y. Cheng Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer Carcinogenesis, December 1, 2007; 28(12): 2451 - 2458. [Abstract] [Full Text] [PDF]

				C. S. Kim, H. Ying, M. C. Willingham, and S.-y. Cheng The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer Carcinogenesis, May 1, 2007; 28(5): 932 - 939. [Abstract] [Full Text] [PDF]

				G. R. Reddy, M. S. Bhojani, P. McConville, J. Moody, B. A. Moffat, D. E. Hall, G. Kim, Y.-E. L. Koo, M. J. Woolliscroft, J. V. Sugai, et al. Vascular Targeted Nanoparticles for Imaging and Treatment of Brain Tumors. Clin. Cancer Res., November 15, 2006; 12(22): 6677 - 6686. [Abstract] [Full Text] [PDF]

				V. Askoxylakis, W. Mier, S. Zitzmann, V. Ehemann, J. Zhang, S. Kramer, C. Beck, M. Schwab, M. Eisenhut, and U. Haberkorn Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells J. Nucl. Med., June 1, 2006; 47(6): 981 - 988. [Abstract] [Full Text] [PDF]

				V. J. Yao, M. G. Ozawa, A. S. Varner, I. M. Kasman, Y. H. Chanthery, R. Pasqualini, W. Arap, and D. M. McDonald Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res., March 1, 2006; 66(5): 2639 - 2649. [Abstract] [Full Text] [PDF]

				V. Askoxylakis, S. Zitzmann, W. Mier, K. Graham, S. Kramer, F. von Wegner, R. H.A. Fink, M. Schwab, M. Eisenhut, and U. Haberkorn Preclinical Evaluation of the Breast Cancer Cell-Binding Peptide, p160 Clin. Cancer Res., September 15, 2005; 11(18): 6705 - 6712. [Abstract] [Full Text] [PDF]

				S. M. Moghimi, A. C. Hunter, and J. C. Murray Nanomedicine: current status and future prospects FASEB J, March 1, 2005; 19(3): 311 - 330. [Abstract] [Full Text] [PDF]

				R. M. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm, G. Molema, P. Y. Lu, P. V. Scaria, and M. C. Woodle Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle Nucleic Acids Res., November 1, 2004; 32(19): e149 - e149. [Abstract] [Full Text] [PDF]

				J. Vellinga, M. J. W. E. Rabelink, S. J. Cramer, D. J. M. van den Wollenberg, H. Van der Meulen, K. N. Leppard, F. J. Fallaux, and R. C. Hoeben Spacers Increase the Accessibility of Peptide Ligands Linked to the Carboxyl Terminus of Adenovirus Minor Capsid Protein IX J. Virol., April 1, 2004; 78(7): 3470 - 3479. [Abstract] [Full Text] [PDF]